A coalition of 86 organizations is urging Congress to pass the Clinical Treatment Act, a bill introduced in January that would guarantee coverage of the routine care costs of clinical trial participation for Medicaid patients with a life-threatening condition.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
